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A characteristic feature of EBV is its ability to transform resting human B cells into permanently growing lymphoblastoid cell lines (LCLs) in vitro. ' In LCL cells and also in posttransplant lymphoproliferative disorders (PTLDs)?'' a limited set of latent viral proteins is expressed, including six Epstein-Barr nuclear antigens (EBNA 1,2, 3A, 3B, 3C, and LP), three latent membrane proteins (LMPl, 2A, and 2B), and two small nuclear, noncoding RNAs (EBER 1 and 2).' However, in other EBV-associated tumors, different forms of EBV latency have been described in which only a subset of viral latent genes is expressed suggesting that the contribution of EBV to the development of virus-associated tumors is va"able.'.''-l3 While several viral latent gene products have been implicated in the process of virus-induced cellular transformation, as yet only LMPl has a well-established oncogenic function, as well as diverse effects on cell phenotype. l~~ On the basis of genetic polymorphism in the EBNA2 and mas and Hodgkin's disease (HD), was examined in the normal population. While a preferential association of the LMPl deletion with the type 2 strain of EBV was observed, there was no increased incidence of virus isolates carrying this deletion in HD, Burktt's lymphoma, or virus-associated carcinomas compared with the appropriate normal population. A polymorphism in the 6amHl F region of the EBV genome, previously identified in Chinese populations, was found at increased incidence in European HD biopsies. Overall, we found that most of the EBV gene polymorphisms detected in EBV isolates from healthy virus carriers occurred with similar frequency in virus-associated tumors from the same geographical region.
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EBNA3 genes, two major virus strains have been identified, EBV types 1 and 2. The results of many studies looking at the frequency of type 1 versus type 2 EBV have shown markedly different frequencies of type 1 and 2 EBV in different geographic location^.'^ In addition to this broad distinction between EBV types 1 and 2, there is also minor heterogeneity within each virus type, which is most easily detected as variation in the size of the EBNA proteins. These differences have been used to trace virus transmission within families and from transplant donors to recipients.I6 Further attempts to identify variability between virus isolates has led to the identification of a defined polymorphism in the BamHI F region of the EBV genome." In contrast to the prototype B95.8 EBV strain ("F" type), EBV genomes from NPC biopsies obtained from Southern Chinese patients were shown to contain an additional BamHI restriction site in this region ('T' variant), whereas this variant was only rarely detected in spontaneous LCLs generated from healthy Southern Chinese or North American donors.'*.'' These observations suggested that the "f" variant of EBV may be implicated in the pathogenesis of NPC. However, it has recently been reported that the "f' EBV variant is not present in NPC specimens from North Africa," an area of intermediate NPC incidence, indicating that the "f' ' polymorphism is not an indispensable prerequisite for NPC development.
Cloning and sequencing of the LMPl gene from EBV isolates derived from Chinese NPCs identified several mutations as compared with the wild-type B95.8 strain, including a point mutation leading to the loss of an XhoI restriction site in the first exon and a 30-bp deletion in the carboxy terminal region of the LMPl gene.21322 It has been suggested that these changes are associated with increased tumorgenicity and reduced immunogenicity of the LMPl prot e i~~. '~. '~ Recently, a similar deletion in the LMPl gene has been found in a proportion of EBV-associated European and certain virus-associated lymphoproliferation~.~~ The LMP 1 gene from different EBV isolates also contains variable numbers of a 33-bp repetitive sequence, which has also been used as a marker of heterogeneity between EBV strains.25
The aim of this study was to analyze specific EBV polymorphisms in virus isolates obtained from healthy individuals in comparison to human lymphoid and epithelial neoplasms from the same geographic location. In particular, polymorphisms in the BamHI F region and in the LMPl gene were analyzed in an attempt to identify disease-associated virus strain variation.
MATERIALS AND METHODS

Cell Culture and Biopsies
Lymphoblastoid cell lines (sp-LCLs) were established from healthy chronic EBV carriers by spontaneous outgrowth of B lymphocytes in culture and maintained in RPMI 1640 medium (GIBCO, Paisley, UK) supplemented with 8% heat inactivated fetal calf serum (FCS), 2 mmollL glutamine, penicillin (120 U/mL), and streptomycin (120 pg/mL) (Sigma, Dorset, UK). Of the donors, 22 were of European origin, 39 were from Africa (Kenya or Gambia), 11 from New Guinea, and 10 were of Chinese extraction. In addition, four LCLs were obtained from Caucasian patients in the acute phase of IM. The African LCLs were generated in our labs through collaboration with Drs H. Rupani, H. Whittle, and K. Lam.'" LCLs from New Guinea were kindly provided by Dr D. Moss (QIMR, Brisbane, Australia). LCLs from Chinese donors were established in our laboratories. Previously established BL cell lines were maintained in RPMI 1640 supplemented with 10% FCS, glutamine, and gentimycin (8 pg/mL). All cultures were grown at 37°C in 5% C02 and passaged weekly.
Formalin-fixed and paraffin-embedded tissue samples from eight patients with IM were included in this study (see Table 2 ). Five lymph nodes and four palatine tonsils were available and have been included in previous studies (G.N. et al, submitted). Histological changes in keeping with acute IM were seen in all cases and this was supported by clinical andor serological information. Furthermore, numerous EBV-infected lymphoid blasts were detected in all IM cases, as described previously (G.N. et al, submitted).
Twenty-five formalin-fixed and paraffin-embedded biopsies of histologically confirmed Hodgkin's disease (HD) were obtained from the files of the Department of Pathology, University of Birmingham, the Department of Pathology, Heartlands Hospital Birmingham, Birmingham, UK (courtesy of Dr J. Crocker) and the Department of Pathology, Bristol Royal Infirmary, Bristol, UK (courtesy of Dr N. Rooney). The EBV status of the cases had been assessed previously using in situ hybridization with RNA probes specific for the small virus-encoded nuclear RNAs (EBERs) as described in detail elsewhere.2" HD cases were selected from previously studied series on the basis of the detection of EBV in the Hodgkin Reed-Sternberg (HRS) cells. The histological subtype of each case IS presented (see Table 3 ).
Ten snap frozen NPC biopsies ( I 17-135 in Table 5 
DNA Extraction
Crude DNA for polymerase chain reaction (PCR) amplification was extracted from LCLs and BLs by incubation of cell pellets in Proteinase K lysis solution (Proteinase K 100 pg/mL, Tween 80 5 pUmL, IO mmoUL Tris HCL (pH 8.3), 50 mmollL KCI. 1.5 mmol/ L MgCI2, and 0.01% gelatin) for 1 hour at 55°C followed by heat inactivation of the enzyme. DNA from frozen biopsies was extracted by proteinase K lysis at 55°C for 1 hour, phenolkhloroform purification and ethanol precipitation. For preparation of DNA from paraffin blocks, 30-pm sections were first deparaffinized with xylene and ethanol and DNA extracted as described above for frozen biopsies.
DNA PCR Amplijication
DNA aliquots (100 ng to 1 pg) were amplified in 100-pL reactions containing 1 pmoVL of each primer. 200 pmol/L dATP, dCTP, dGTP, and dTTP, IO mmoUL Tris HC1 (pH 8.8), 1.5 mmoVL MgClz, 50 mmoVL KCI, 0.1% Triton X-100, and overlaid with mineral oil. The samples were denatured for 5 minutes at 94°C. Two units of Taq polymerase were added and PCR amplification performed in a Perkin Elmer-Cetus (Warrington, UK) 480 Thermal Cycler. The primer combinations used, cycle parameters for PCR amplification, and product sizes of the different regions of EBV are described in Table 1 .
Restriction Fragment Length Polymorphism Analysis
To perform an analysis of the BamHI F and XhoI polymorphisms, amplified PCR DNA was purified by phenokhloroform extraction followed by ethanol precipitation with glycogen carrier. DNA pellets were resuspended in 50 pL distilled water and 5 pL aliquots were digested with 20 U of either BamHI for the BamHI F restriction fragment length polymorphism (RFLP) and XhoI for the XhoI RFLP (Boehringer Mannheim, Germany). Restriction enzyme digests were performed in 20 pL volumes according to manufacturer's instructions and the results analyzed on polyacrylamide gels as described below.
Analysis of PCR and RFLP Products
To analyze the products of the PCR amplifications, samples were electrophoresed on 10% to 15% polyacrylamide gels and bands visualized by ethidium bromide staining. Specificity of the PCR reactions was confirmed by hybridization with oligonucleotide probes as de- at room temperature with 2 X SSC, 0.1% SDS, and 1 X SSC, 0.1% SDS and exposed to Kodak autoradiographic film (Heme1 Hempsted, UK).
Cycle Sequencing
DNA for cycle sequencing was purified from low melting point agarose gels using the Wizard PCR Prep kit (Promega, UK). Sequencing was carried out with 32P-5' end-labelled oligonucleotide primers and the Amplitaq Cycle Sequencing kit (Perkin Elmer-Cetus, UK) according to manufacturer's instructions. Sequences were analyzed by electrophoresis on 6% 6 m o m urea polyacrylamide gels and autoradiography.
RESULTS
Validation of PCR Methodology
Each isolate reported in this study was analyzed for polymorphisms in six different regions of the EBV genome. EBV strain type was determined over two of the latent EBV genes, EBNA2 and EBNA3C, using well-characterized primers and amplification conditions from Sample et aLZ9 Type 2 EBV isolates were specifically included in this study for analysis of the various polymorphic markers, therefore the percentages of type 1 EBV to type 2 EBV in the study groups are not representative of infection levels in the general population. Extensive studies have already been performed by our group and other groups looking at the incidence of the two EBV types in various geographic populations (for review see Gratama et aii5).
The "F" and "f" RFLP was detected by PCR amplification over the BamHI F fragment of EBV, purifying the products and digesting with BamHI restriction enzyme as previousiy described." EBV isolates carrying the wild-type "F" yielded a single undigested product of 222-bp (Fig   1) . However, in isolates carrying the "f' variant, BamHI digestion of the PCR product results in the generation of two fragments of 126 bp and 96 bp (Fig 1) . To verify the mutation in "f" virus isolates, nine isolates carrying either the wild-type "F" or the "f" variant (sp-LCLs: D5, DH, QX, QY, FJW, JLU, L10, H32, H36) were sequenced alongside B95.8, and in all "f" cases there was an A to C transversion at position 55707 (B95.8 coordinates) creating the extra BamHI site. A similar PCR approach was used to identify the XhoI RFLP in the LMPl gene. XhoI digestion of the PCR products from EBV strains, which retained the XhoI site, yielded two products of 345 bp and 144 bp, whereas EBV isolates with a mutated XhoI site yielded an undigested band of 489-bp (Fig 1) . PCR products of nine randomly selected isolates with or without the XhoI site (B95.8, AG876, SWE, IM12, IM50, D5, QX, CKL, MTL) were sequenced over the XhoI site revealing an identical G to T transversion in codon 17 of the LMPl gene as described previouslyz5~30 (data not shown).
The LMPl gene was analyzed over the 33-bp repeat region by PCR followed by polyacrylamide gel electrophoresis, blotting, and probing with a specific oligonucleotide probe (Fig 1) . Differences were easily detectable and the numbers of repeats calculated with the aid of a 20-bp size marker. For nine isolates (B95.8, AG876, GA490, M192, FJW, JLU, MTL, 124, 125) the number of repeats was confirmed by sequencing the PCR product. In agreement with previously published results, a single band was noticed in all virusassociated tumors (Tables 3 through 6 cell lines, which had been generated by infection with the B95.8 virus isolate, were also studied (data not shown), and in all cases, the PCR assay yielded a band representing 4.5 x 33-bp LMPl repeats as in the original B95.8 cell line, thus confirming the stability of the number of LMPl repeats in a virus isolate over time.
The 30-bp deletion in the LMPl gene was detected by PCR and subsequent blotting and probing. EBV isolates with a deleted LMPl gene yielded a smaller product of 230 bp compared with the full-length product of 260 bp (Fig I) . All PCR products obtained from isolates with the LMPl deletion were of identical size suggesting lack of variability in the deleted region. This was confirmed by sequence analysis of I O isolates, six that did not carry the LMPl deletion (B95.8, TIE, DAV, ROG, BYR, IM50) and four that were deleted (AG876, IM12, MOR, BEV), and this showed a consistent location of the 30-bp deletion between amino acids 343 and 352 (data not shown) as reported by Miller et al."
Comparison of EBV 1.solate.s From Normal Donors, Hod<qkin's Disease Biopsies, and NPC Biopsies of
European Origin
Of the 26 European spontaneous LCLs (sp-LCLs), 21 (8 1 %) harbored EBV type I , and 5 (1 9%) carried type 2 as determined using PCR over the EBNA2 and EBNA3c re- gions of the viral genome with previously validated primer combinations ( (Table 3 ). All European sp-LCLs displayed the"F" wild-type configuration as in the B95.8 prototype EBV strain (Table 2) . Of the seven IM biopsies that were available for BamHI F RFLP analysis, six displayed the wild-type "F" configuration, whereas one showed the "f' form (Table 2) . Unexpectedly, I O of the 22 HD cases (45%) harbored EBV with the "f" variant (Table 3 , Fig 2A) . By contrast, the "f" variant was detected in only one of IO (10%) Caucasian NPC biopsies and was not present in the two gastric carcinomas that were available for analysis (Table 3) .
In analyzing the LMPl gene from the European EBV isolates, it was noted that variation in the number of LMPl repeats was quite limited in the type 2 EBV isolates from this group; however, a much greater degree of variation was noted in the type 1 EBV isolates (Fig 2B) . In all cases, a single band was observed, with the exception of one IM biopsy in which two
Polymorphisms in the LMPI gene.
For Abbreviations: sp-LCL, Spontaneous LCL; wt, similar to that seen in the 695.8 EBV prototype virus; F, absence of a 6amHl site in the 8amHl F fragment of the EBV genome; f, presence of an extra 8amHl site in the BamHl F fragment of the EBV genome; lost, loss of the Xhol site in LMPl as a result of a G to C base transition; del, presence of a 30-bp deletion in the carboxy terminus of the LMPl gene; -, result not obtained.
major bands representing 4.5 and 8 to 9 repeats, respectively, were found, and these may have resulted from recombination events associated with virus replication. Twenty-four of 26 European sp-LCLs (92%) and all IM biopsies carried EBV with wild-type configuration of the XhoI site, whereas two LCL isolates (8%) had lost this restriction enzyme site ( Table  2 ). The XhoI site was preserved in all virus isolates derived from European HD biopsies, NPC biopsies, and gastric adenocarcinomas (Table 3) .
In European sp-LCLs, nine of 22 (41%) virus isolates displayed the 30-bp LMPl deletion ( biopsies, five of 10 (50%) European NPC biopsies, and two of four gastric adenocarcinomas ( Table 3) .
Comparison of EBV Isolates From Normal Donors and Burkitt Lymphoma Cell Lines of African and New Guinean Origin
Thirty-three (85%) sp-LCLs from African individuals carried type 1 EBV and six (15%) contained type 2 virus (Table  4 ). Of the 1 1 African BL lines selected for this study, seven carried EBV type I and four harbored type 2 virus (Table  4) . For comparison, we also included LCLs and BL lines from New Guinea ( Table 5 ). All LCLs and one BL cell line from this location contained EBV type I and 2 BL lines harbored type 2 EBV (Table 5 ). All African sp-LCLs carried EBV strains with the "F" wild-type configuration, as did all African BL lines (Table 4) . One New Guinean LCL showed the "f" variant, whereas the remaining 10 LCLs and all three BL lines exhibited the "F" wild-type virus (Table 5) .
PCR amplification of the LMPl repeat region showed limited variation in the numbers of the 33-bp repeat sequences in EBV isolates from African and New Guinean normal donors sp-LCLs and also in EBV isolates from BL cell lines (Fig 3A) . Two of 39 African sp-LCLs (5%) carried virus with loss of the XhoI site in the LMPl gene (Table 4 ). In the 1 1 New Guinean LCLs, three virus isolates lacking the XhoI site were identified, while the remaining eight lines carried virus with an intact XhoI site ( Table 5 ). All 1 1 African BL lines and the three BL lines from New Guinea displayed EBV isolates with a preserved XhoI site.
The 30-bp LMPl deletion was found in 10 of the 39 (26%) African spontaneous LCLs (Table 4 , Fig 3B) . As in the European isolates, there was an association of the LMPl deletion with type 2 virus. Five of six (83%) African LCLs with type 2 virus carried the LMPl deletion, whereas only five of 33 (15.2%) type 1 isolates displayed this polymorphism (Table 4 , Fig 3B) . Also, there seemed to be some variability among normal isolates from Kenya and from Polymorphisms in the LMPI gene.
Gambia. All Gambian isolates were of type I, but four of 14 (28.6%) displayed the LMPI deletion. By contrast, only one of 19 (5.3%) type 1 EBV isolates from Kenya demonstrated the 30-bp deletion in the LMPl gene (Table 4) . A similar distribution was noted in the African BL isolates where the 30-bp deletion was found in one of seven (14.3%) BLs carrying type 1 EBV and in 2 of 4 (50%) BLs carrying type 2 EBV (Table 4) . None of the spontaneous LCLs or BL cell lines from New Guinea carried EBV isolates with the LMPl deletion.
Comparison of EBV Isolntes From Normal Donors and
From NPC Biopsies of Southeast Asian Origin
Nine of 10 Chinese sp-LCLs harbored type 1 EBV and one contained type 2 virus (Table 6) . Similarly, all NPC biopsies except one carried type 1 EBV (Table 6 ). Of the Chinese sp-LCLs. three lines (30%) displayed the "f" EBV variant (Table 6 , Fig I) . The "f' polymorphism was demonstrated in 13 of 19 (68.4%) NPC biopsies from Chinese individuals. There were no significant differences between biopsies obtained from Hong Kong and from Taiwan (Table  6) .
Little variation was observed in the number of 33-bp repeats in EBV isolates from normal Chinese donors and from NPC biopsies (between three and six repeats, Table 6 ). In contrast to the spontaneous LCLs from Europe, Africa, and New Guinea, the sp-LCLs from donors of Chinese extraction demonstrated loss of the XhoI site in nine of 10 cases (90%. Table 6 , Fig  4A) . The one LCL carrying a preserved XhoI site was unusual in that it harbored type 2 EBV and also differed from all other lines with respect to the 30-bp LMPl deletion ( Fig  4B) . All virus isolates from Chinese NPC biopsies displayed loss of the XhoI site in the LMPl gene (Table 6 , Fig 4A) . All nine Chinese sp-LCL type 1 EBV isolates displayed the 30-bp LMPl deletion, and one LCL contained type 2 virus with a full-length LMPl gene (Fig 4B) . Accordingly, all 19 Chinese NPC isolates were of type 1 and displayed the LMPl deletion (Table 6 , Fig 4B) .
Polymorphisms in the LMPI gene.
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DISCUSSION
While EBV is associated with a wide range of human malignancies, the contribution of EBV strain variation to the pathogenesis of such tumors is unknown. Several groups have recently proposed that certain EBV gene polymorphisms may be specifically associated with some virus-positive tumors and may confer a more aggressive malignant phen~type.'~.~' To test this hypothesis, we have undertaken an analysis of EBV isolates from different lymphoid and epithelial malignancies and compared these with virus isolates present in the normal population. We have focused particularly on specific polymorphisms in the LMPl gene and in the BamHI F fragment of the EBV genome.
LMPl genes carrying point mutations leading to the loss of an XhoI restriction site in the first exon and a 30-bp deletion in the carboxy terminal region were first identified in virus isolates derived from Chinese NPC biopsies."." The deletion overlaps with one of the putative functional domains in the carboxy terminus of LMPl, and it has been suggested that this variant LMPl may be more oncogenic, but less immunogenic, than the prototype B95.8 LMPl .'4, 23 In the present study, we confirm the presence of LMPl genes carrying both the XhoI polymorphism and the LMPl deletion in all NPC biopsies from Hong Kong and Taiwan. These polymorphisms were also detected in the majority of EBV isolates from healthy Chinese donors suggesting that the presence of variant LMPl in NPC simply reflects the overall prevalence of this polymorphism in EBV strains infecting the general Chinese population. This assertion is supported by our analysis of EBV-positive NPCs and gastric adenocarcinomas from European individuals where the incidence of EBV strains carrying the 30-bp LMPl deletion is identical to that observed in normal European donors. However, an interesting observation is the absence of the XhoI polymorphism from all carcinoma isolates and from virtually all virus isolates from healthy European and African donors carrying This supports our contention that there is geographic variation in the prevalence of certain EBV isolates and that this is reflected in the virus isolates found in EBV-associated tumors common to these locations. This would also help to explain the high incidence of EBV isolates carrying the LMPl deletion in Tcell lymphomas in Chinese populations. 33 The Chinese isolates were also different from all other groups with respect to the relationship between virus type and presence or absence of the LMPl deletion. Thus, almost all isolates from Chinese individuals were of type 1 and displayed the LMPl deletion. By contrast, isolates obtained from all other geographic areas analyzed showed a preferential association of the LMPl deletion with type 2 virus, such that 11 of 16 (69%) type 2 isolates carried the deletion compared with 23 of 1 18 (19%) type 1 isolates. This association was particularly evident in Africa where infection with type 2 EBV is more common. The analysis of EBV strains in Africa and New Guinea confirms and extends our previous study'" and demonstrates that neither type 2 virus nor the LMPl deletion is preferentially associated with BL.
Previous studies reported the presence of LMPl variants carrying the 30-bp deletion in 10% to 30% of EBV-positive HD cases and in various lymphoproliferative disease^.^^.^'.^^
In agreement with these studies, we identified 9% of HD cases that carried the deletion. In their original study, Knecht et a13' suggested that EBV isolates with the LMPl deletion are preferentially found in histologically aggressive forms of HD. and this contention is supported by a more recent study." In our series, the two HD cases harboring LMPIdeleted EBV were of the mixed cellularity histotype, which is more frequently associated with EBV infection. All four HD cases displaying histological signs of particular aggressiveness (ie, necrosis and/or pleomorphic HRS cells) harbored virus with the full-length LMPl gene. Thus, our findings do not support the association of LMPI-deleted EBV with aggressive HD, but further studies of a larger number of cases are required and the criteria for determining aggressive tumors (ie, histiotype, stage at presentation, treatment responsiveness) needs to be more thoroughly examined. The incidence of the LMPl deletion in normal populations has not been extensively examined previously. In the current study, this deletion was found in 41% of LCLs derived from normal healthy European donors and in 50% of IM tissues. Interestingly, results from another study identified the 30-bp deletion in three of nine IM (30%) tissues from a Danish population.34 These results, together with the data from the series of HD biopsies studied, suggest that EBV isolates carrying the LMPl deletion do not significantly increase the risk of developing HD. However, the recent demonstration that the 30-bp deleted LMPl is always found in HIV-associated HD3' endorses the possible increased oncogenic capacity of this variant and also raises questions about the prevalence of this virus in the HIV-infected population. Our results support the contention that the occurrence of EBV isolates carrying the 30-bp LMPl deletion in HD reflects the overall prevalence of this polymorphism in EBV strains infecting the general population. The increased incidence of type 2 EBV in HIV-infected individuals"~."" may explain the prevalence of the LMPl deletion variant in HIV-associated HD, as our data suggest a preferential association of the deletion with type 2 virus. Clearly, the possibility that HIV-infected individuals are infected with more than one strain of EBV and that some of these strains may predispose to certain EBV-associated tumors needs to be examined. In this context, it is interesting that the B-cell lymphomas arising in HIV-positive patients are frequently found to carry type 2 EBV and thus may also harbor deleted LMP1.37 Recently published work demonstrating that patients with multifocal HD can harbor both wild-type and deleted LMPl carrying EBV isolates suggests that either infection with multiple EBV strains is possible or that the LMPl deletion occurs as a late event in the oncogenic process." Other mutational hotspots have been identified in the carboxy terminus of the LMPl gene including several point mutations," and these may also contribute to the tumorigenicity of EBV. However, the frequency of these point mutations in EBV isolates is not known, and thus future studies examining the prevalence of these hotspots are warranted.
A notable feature of EBV strains from the Chinese population was the high prevalence of isolates carrying the BamHI F fragment polymorphism or so-called 'f variant. Thus, in agreement with previous the majority of NPC biopsies (68%) from Chinese patients carried the "f' polymorphism, but this variant was only observed in 30% of virus isolates from healthy Chinese donors suggesting a possible association of this variant with the development of NPC.
However, the "f' polymorphism was identified in only one of I I (9%) European NPC biopsies and was not found in any European LCLs. but was detected in one of seven IM biopsies, and in one of 50 LCLs from Africa and New Guinea. Interestingly, we found an increased incidence of virus isolates containing the "f' polymorphism in HD biopsies from European patients. This was unexpected. as to date, this variant has only been described in Chinese populations. The implication of this finding with regard to the role of EBV in the pathogenesis of HD remains obscure. Although several open reading frames (ORF) have been identified in the BamHI F fragment of EBV, no specific viral function has yet been attributed to this region, and it may be that this variation is a surrogate marker of a particular strain of EBV with polymorphisms at other sites of the viral genome. Previous studies have suggested that variations in the number of 33-bp repeats in the LMPl gene between different virus isolates may be useful for the determination of the clonality of the EBV-carrying cell population>" Thus, it has been argued that polyclonal EBV-carrying cell populations For personal use only. on October 27, 2017. by guest www.bloodjournal.org From should display LMPl repeat sequences of variable lengths, while monoclonal proliferations would harbor only one virus isolate with a defined number of repeats. Here we confirm that PCR analysis of this region yields a single band in all virus-associated malignancies. However, a single band was also identified in all but one biopsy from individuals with the polyclonal EBV-associated lymphoproliferative disease, IM, suggesting that this polymorphism is not a suitable marker for the determination of the cionality of virus-carrying cell populations.
In summary, although this is not a comprehensive epidemiological study, our results suggest that the specific EBV gene polymorphisms detected in virus-associated tumors occur with similar frequencies in EBV isolates from healthy virus carriers from the same geographic region. The only exception to this is the "f" variant, which was detected with increased frequency in both Chinese NPC biopsies and in European HD tissues. While EBV isolates carrying the LMPl deletion are found in a similar proportion of healthy EBV carriers and virus-associated tumors from the same geographic area, it remains possible that this LMPl variant may influence the efficiency of malignant transformation, thereby contributing to the increased incidence of certain EBV-associated tumors in regions where this polymorphism is common.
